HDL (High-Density Lipoprotein) and ApoA-1 (Apolipoprotein A-1) Potentially Modulate Pancreatic α-Cell Glucagon Secretion

Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2941-2952. doi: 10.1161/ATVBAHA.120.314640. Epub 2020 Oct 22.

Abstract

Objective: Subjects with low levels of HDL (high-density lipoprotein) and ApoA-1 (apolipoprotein A-1) have increased risk to develop type 2 diabetes. HDL levels are an independent predictor of β-cell function and positively modulate it. Type 2 diabetes is characterized by defects in both β and α-cell function, but the effect of HDL and ApoA1 on α-cell function is unknown. Approach and Results: We observed a significant negative correlation (r=-0.422, P<0.0001) between HDL levels and fasting glucagon in a cohort of 132 Italian subjects. In a multivariable regression analysis including potential confounders such as age, sex, BMI, triglycerides, total cholesterol, fasting and 2-hour postload glucose, and fasting insulin, the association between HDL and fasting glucagon remained statistically significant (β=-0.318, P=0.006). CD1 mice treated with HDL or ApoA-1 for 3 consecutive days showed a 32% (P<0.001) and 23% (P<0.05) reduction, respectively, in glucagon levels following insulin-induced hypoglycemia, compared with controls. Treatment of pancreatic αTC1 clone 6 cells with HDL or ApoA-1 for 24 hours resulted in a significant reduction of glucagon expression (P<0.04) and secretion (P<0.01) after an hypoglycemic stimulus and increased Akt (RAC-alpha serine/threonine-protein kinase) and FoxO1 (forkhead/winged helix box gene, group O-1) phosphorylation. Pretreatment with Akt inhibitor VIII, PI3K (phosphatidylinositol 3-kinase) inhibitor LY294002, and HDL receptor SCARB-1 (scavenger receptor class B type 1) inhibitor BLT-1 (block lipid transport-1) restored αTC1 cell response to low glucose levels.

Conclusions: These results support the notion that HDL and ApoA-1 modulate glucagon expression and secretion by binding their cognate receptor SCARB-1, and activating the PI3K/Akt/FoxO1 signaling cascade in an in vitro α-cell model. Overall, these results raise the hypothesis that HDL and ApoA-1 may have a role in modulating glucagon secretion.

Keywords: apolipoprotein A-I; blood glucose; cholesterol, HDL; diabetes mellitus; glucagon; glucagon-secreting cells; type 2.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Animals
  • Apolipoprotein A-I / blood
  • Apolipoprotein A-I / pharmacology*
  • Cell Line
  • Female
  • Forkhead Box Protein O1 / metabolism
  • Glucagon / blood*
  • Glucagon-Secreting Cells / drug effects*
  • Glucagon-Secreting Cells / metabolism
  • Glucose Tolerance Test
  • Humans
  • Italy
  • Lipoproteins, HDL / blood
  • Lipoproteins, HDL / pharmacology*
  • Male
  • Mice, Inbred ICR
  • Middle Aged
  • Phosphatidylinositol 3-Kinase / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Scavenger Receptors, Class B / metabolism
  • Secretory Pathway
  • Signal Transduction
  • Time Factors

Substances

  • APOA1 protein, human
  • Apolipoprotein A-I
  • Forkhead Box Protein O1
  • Foxo1 protein, mouse
  • Lipoproteins, HDL
  • Scarb1 protein, mouse
  • Scavenger Receptors, Class B
  • Glucagon
  • Phosphatidylinositol 3-Kinase
  • Proto-Oncogene Proteins c-akt